The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Yang, Dong ^a,b   Tan, Mingjia ^a   Wang, Gongxian ^b   Sun, Yi ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NANCHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CULLIN; ENZYME INHIBITOR; MLN 4924; PROTEIN P21; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ((1S,2S,4R) 4 (4 ((1S) 2,3 DIHYDRO 1H INDEN 1 YLAMINO) 7H PYRROLO(2,3 D)PYRIMIDIN 7 YL) 2 HYDROXYCYCLOPENTYL)METHYL SULPHAMATE; ((1S,2S,4R)-4-(4-((1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO)-7H-PYRROLO(2,3-D)PYRIMIDIN-7-YL)-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE; CYCLOPENTANE DERIVATIVE; NEDD8 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; RADIOSENSITIZING AGENT; SMALL INTERFERING RNA; UBIQUITIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; ENZYME INACTIVATION; HUMAN; HUMAN CELL; RADIOSENSITIZATION; BREAST TUMOR; CELL CYCLE; DRUG ANTAGONISM; FEMALE; FLOW CYTOMETRY; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE; VALIDATION STUDY;

APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CYCLOPENTANES; FEMALE; FLOW CYTOMETRY; HUMANS; ONCOGENE PROTEIN P21(RAS); PYRIMIDINES; RADIATION-SENSITIZING AGENTS; RNA, SMALL INTERFERING; UBIQUITINS;

EID: 84863380384     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034079     Document Type: Article

References (58)

1. Deshaies RJ, Joazeiro CA, (2009) RING domain E3 ubiquitin ligases. Annu Rev Biochem 78: 399-434.
2. Nakayama KI, Nakayama K, (2006) Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6: 369-381.
3. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, et al. (2002) Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 416: 703-709.
4. Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, et al. (2004) Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev 18: 2573-2580.
5. Wu K, Fuchs SY, Chen A, Tan P, Gomez C, et al. (2000) The SCF(HOS/beta-TRCP)-ROC1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation. Mol Cell Biol 20: 1382-1393.
6. Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M, et al. (2008) Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 134: 995-1006.
7. Goldenberg SJ, Cascio TC, Shumway SD, Garbutt KC, Liu J, et al. (2004) Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases. Cell 119: 517-528.
8. Kamura T, Conrad MN, Yan Q, Conaway RC, Conaway JW, (1999) The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev 13: 2928-2933.
9. Yamoah K, Oashi T, Sarikas A, Gazdoiu S, Osman R, et al. (2008) Autoinhibitory regulation of SCF-mediated ubiquitination by human cullin 1's C-terminal tail. Proc Natl Acad Sci U S A 105: 12230-12235.
10. Nalepa G, Rolfe M, Harper JW, (2006) Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 5: 596-613.
11. Sun Y, (2003) Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Therapy 2: 623-629.
12. Sun Y, (2006) E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 8: 645-654.
13. Jia L, Sun Y, (2011) SCF E3 ubiquitin ligases as anticancer targets. Current Cancer Drug Targets 11: 347-356.
14. Sun Y, (2005) Overview of approaches for screening for ubiquitin ligase inhibitors. Methods Enzymol 399: 654-663.
15. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, et al. (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458: 732-736.
16. Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, et al. (2010) Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 37: 102-111.
17. Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, et al. (2010) MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 116: 1515-1523.
18. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, et al. (2010) Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 115: 3796-3800.
19. Jia L, Li H, Sun Y, (2011) Induction of p21-Dependent Senescence by an NAE Inhibitor, MLN4924, as a Mechanism of Growth Suppression. Neoplasia 13: 561-569.
20. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, et al. (2010) Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464: 374-379.
21. Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A, (2010) NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 70: 10310-10320.
22. Soucy TA, Smith PG, Rolfe M, (2009) Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 15: 3912-3916.
23. Jia L, Soengas MS, Sun Y, (2009) ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res 69: 4974-4982.
24. Jia L, Yang J, Hao X, Zheng M, He H, et al. (2010) Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target. Clin Cancer Res 16: 814-824.
25. Jia L, Bickel JS, Wu J, Morgan MA, Li H, et al. (2011) RBX1 (RING-box protein 1) E3 ubiquitin ligase is required for genomic integrity by modulating DNA replication licensing proteins. J Biol Chem 286: 3379-3386.
26. Tan M, Zhu Y, Kovacev J, Zhao Y, Pan ZQ, et al. (2010) Disruption of Sag/Rbx2/Roc2 induces radiosensitization by increasing ROS levels and blocking NF-kB activation in mouse embryonic stem cells. Free Radic Biol Med 49: 976-983.
27. Wei D, Li H, Yu J, Sebolt JT, Zhao L, et al. (2012) Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res 72: 282-293.
28. Fertil B, Dertinger H, Courdi A, Malaise EP, (1984) Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 99: 73-84.
29. Zheng M, Morgan-Lappe SE, Yang J, Bockbrader KM, Pamarthy D, et al. (2008) Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res 68: 7570-7578.
30. Bockbrader KM, Tan M, Sun Y, (2005) A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 24: 7381-7388.
31. Wasielewski M, Elstrodt F, Klijn JG, Berns EM, Schutte M, (2006) Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. Breast Cancer Res Treat 99: 97-101.
32. Yang D, Zhao Y, Li AY, Wang S, Wang G, et al. (2011) Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis. Breast Cancer Res Treat 2011/09/09: [Epub ahead of print] PMID: 21901386.
33. Yang J, McEachern D, Li W, Davis MA, Li H, et al. (2011) Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases. Mol Cancer Ther 10: 658-669.
34. Begg AC, Stewart FA, Vens C, (2011) Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11: 239-253.
35. Kee Y, Huang M, Chang S, Moreau L, Park E, et al. (2012) Inhibition of the Nedd8 system sensitizes cells to DNA Interstrand crosslinking agents. Mol Cancer Res 2012/01/06 [Epub ahead of print], PMID: 22219386.
36. Skaar JR, D'Angiolella V, Pagan JK, Pagano M, (2009) SnapShot: F Box Proteins II. Cell 137: 1358 1358e1351.
37. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
38. Higgins MJ, Baselga J, (2011) Targeted therapies for breast cancer. J Clin Invest 121: 3797-3803.
39. Malmstrom P, Holmberg L, Anderson H, Mattsson J, Jonsson PE, et al. (2003) Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. Eur J Cancer 39: 1690-1697.
40. Lyons JA, Woods C, Galanopoulos N, Silverman P, (2011) Emerging radiation techniques for early-stage breast cancer after breast-conserving surgery. Future Oncol 7: 915-925.
41. Jameel JK, Rao VS, Cawkwell L, Drew PJ, (2004) Radioresistance in carcinoma of the breast. Breast 13: 452-460.
42. Debeb BG, Xu W, Woodward WA, (2009) Radiation resistance of breast cancer stem cells: understanding the clinical framework. J Mammary Gland Biol Neoplasia 14: 11-17.
43. Tang W, Li Y, Yu D, Thomas-Tikhonenko A, Spiegelman VS, et al. (2005) Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells. Cancer Res 65: 1904-1908.
44. el Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
45. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ, (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
46. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, et al. (1993) p21 is a universal inhibitor of cyclin kinases [see comments]. Nature 366: 701-704.
47. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
48. el Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, et al. (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174.
49. Smits VA, Klompmaker R, Vallenius T, Rijksen G, Makela TP, et al. (2000) p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J Biol Chem 275: 30638-30643.
50. Medema RH, Klompmaker R, Smits VA, Rijksen G, (1998) p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene 16: 431-441.
51. Niculescu AB 3rd, Chen X, Smeets M, Hengst L, Prives C, et al. (1998) Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18: 629-643.
52. Baus F, Gire V, Fisher D, Piette J, Dulic V, (2003) Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts. EMBO J 22: 3992-4002.
53. Biggs JR, Kudlow JE, Kraft AS, (1996) The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J Biol Chem 271: 901-906.
54. Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, et al. (2006) Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat Oncol 1: 25.
55. Sanli T, Rashid A, Liu C, Harding S, Bristow RG, et al. (2010) Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys 78: 221-229.
56. Yu ZK, Gervais JL, Zhang H, (1998) Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci U S A 95: 11324-11329.
57. Chargari C, Leteur C, Angevin E, Bashir T, Schoentjes B, et al. (2011) Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett 312: 209-218.
58. Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, et al. (2006) Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 6: 107.